From Yahoo Finance: 2025-05-27 09:29:00

Carillon Tower Advisers released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. Small-cap stocks dropped significantly in Q1, with the Russell 2000 Growth Index down 11.12%. Real estate outperformed all sectors, rising by 1.76%. Consumer staples also saw a positive return of 0.67%. Check the fund’s top five holdings for its best picks in 2025.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was highlighted in Carillon Eagle Small Cap Growth Fund’s Q1 2025 investor letter. The biopharmaceutical company saw a one-month return of 2.86% and shares gained 50.15% over the last 52 weeks. On May 23, 2025, PTGX stock closed at $45.66 per share with a market cap of $2.83 billion.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is focused on developing drugs for rare diseases like polycythemia vera and ulcerative colitis. A major pharmaceutical company announced positive results for icotrokinra in a phase 2 trial for ulcerative colitis, contributing to the stock’s strong performance in Q1 2025. PTGX is not among the 30 most popular stocks among hedge funds.



Read more at Yahoo Finance: Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome